Moderna introduced Monday {that a} booster shot of its COVID-19 vaccine considerably will increase antibody ranges towards the highly-transmissible Omicron variant.
A 50 microgram jab — the licensed dose for a 3rd shot — noticed a 37-fold enhance in neutralizing antibodies, the vaccine maker mentioned.
Moderna additionally examined a 100 microgram booster dose, which elevated antibody ranges 83-fold. The primary two pictures of Moderna’s vaccine are each 100 micrograms.
The corporate mentioned the upper booster dose was typically protected and well-tolerated, though there was a development towards barely extra frequent hostile reactions.
Moderna CEO Stephane Bancel known as the info “reassuring” however mentioned it can proceed to “quickly advance an omicron-specific booster candidate into scientific testing in case it turns into vital sooner or later.”
Nevertheless, for now, the drugmaker mentioned the present model of its vaccine – mRNA-1273 — will proceed to be its “first line of protection towards Omicron.”
“What we have now obtainable proper now could be 1273,” Dr. Paul Burton, Moderna’s chief medical officer, told Reuters.
“It’s extremely efficient, and it’s extraordinarily protected. I feel it can shield folks by the approaching vacation interval and thru these winter months, after we’re going to see essentially the most extreme strain of Omicron,” he added.
The info, which has not but been peer-reviewed, examined blood from 20 booster recipients with every dose towards a pseudovirus engineered to resemble the Omicron variant, the corporate mentioned.
Antibody ranges had been measured on day 29 post-boost.
Burton mentioned it might be as much as governments and regulators to evaluate whether or not they need the improved degree of safety {that a} 100 microgram dose may present.
US regulators licensed Moderna’s 50 microgram booster in October.
